Cheng Chang

发表

Structure-Based Design of Irreversible Human KAT II Inhibitors: Discovery of New Potency-Enhancing Interactions.

J. Pandit, Ji-Young Kim, P. Verhoest, 2013, ACS medicinal chemistry letters.

Quantitative Translational Analysis of Brain Kynurenic Acid Modulation via Irreversible Kynurenine Aminotransferase II Inhibition

K. A. Welch, T. Maurer, P. Verhoest, 2018, Molecular Pharmacology.

11β-Hydroxysteroid Dehydrogenase 1 Human Tissue Distribution, Selective Inhibitor, and Role in Doxorubicin Metabolism

L. Di, Sangwoo Ryu, Hui Zhang, 2018, Drug Metabolism and Disposition.

Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.

Laura McDowell, Scot Mente, Mihaly Hajos, 2017, Journal of medicinal chemistry.

Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors

Graham M. West, Sherry L. Niessen, Claude Ambroise, 2016, Nature Communications.

Preclinical Evaluation of 18F-PF-05270430, a Novel PET Radioligand for the Phosphodiesterase 2A Enzyme

Yiyun Huang, R. Carson, J. Ropchan, 2016, The Journal of Nuclear Medicine.

Preclinical Evaluation of 18 FPF-05270430 , a Novel PET Radioligand for the Phosphodiesterase 2 A Enzyme

Yiyun Huang, R. Carson, J. Ropchan, 2016 .

The discovery and characterization of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiator N-{(3S,4S)-4-[4-(5-cyano-2-thienyl)phenoxy]tetrahydrofuran-3-yl}propane-2-sulfonamide (PF-04958242).

J. Pandit, R. Hurst, M. Hajós, 2015, Journal of medicinal chemistry.

Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation.

Claude Ambroise, D. Karanian, K. Bales, 2018, Journal of medicinal chemistry.

Bridging Efficacy of Tofacitinib Immediate‐Release to Extended‐Release Formulations for Treatment of Ulcerative Colitis: Application of a Model‐Informed Drug Development Approach

J. Kushner, T. Nicholas, C. Su, 2022, Clinical pharmacology in drug development.

Systems approach reveals photosensitivity and PER2 level as determinants of clock‐modulator efficacy

Jae Kyoung Kim, Travis T Wager, A. Doran, 2019, Molecular systems biology.

Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate.

J. Pandit, W. Hoffman, M. Hajós, 2018, Journal of medicinal chemistry.

The development and validation of a computational model to predict rat liver microsomal clearance.

E. Gifford, D. B. Duignan, Kjell Johnson, 2009, Journal of pharmaceutical sciences.

Discovery of hydroxamate bioisosteres as KAT II inhibitors with improved oral bioavailability and pharmacokinetics

J. Pandit, R. Obach, Ji-Young Kim, 2013 .

Quantitative Analysis of 18F-PF-06684511, a Novel PET Radioligand for Selective β-Secretase 1 Imaging, in Nonhuman Primate Brain

C. Halldin, L. Chen, A. Takano, 2018, The Journal of Nuclear Medicine.

Late-Stage Microsomal Oxidation Reduces Drug–Drug Interaction and Identifies Phosphodiesterase 2A Inhibitor PF-06815189

G. S. Walker, A. Stepan, R. Obach, 2018, ACS Medicinal Chemistry Letters.